Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of JHM03 for improvement of moderate to severe glabellar lines
CTR20250490Phase 3Completed
- Sponsor
- Junhemeng Biopharmaceutical
- Start
- Apr 2025
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, double-blind, single-arm trial of JHM03 in glabellar furrowing, sponsored by Junhemeng Biopharmaceutical. Primary endpoint: Composite responder rate for glabellar line improvement at maximum frown. Started Apr 2025; status: completed.
02
Drugs
JHM03
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on CTR20250490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250490.